[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Multiple Sclerosis - Payer Insight: Update Bulletin [April 2017]

March 2017 | | ID: MC0764FAF95EN
FirstWord

US$ 1,045.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Topics covered in this update include: payers’ approaches to the reimbursement of Ocrevus (ocrelizumab; Roche/Biogen) for relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS); the impact of the launch delay of generic Copaxone 40mg/ml and potential steps that Teva could take to retain market share of its branded Copaxone; approaches to reimbursing Alkermes’ ALKS 8700 and opinions on ways by which Biogen could retain market share of Tecfidera.

BUSINESS QUESTIONS:
  • How do payers react to the recent approval of ocrelizumab?
  • How is ocrelizumab likely to be covered in the US?
  • How do US payers feel about ocrelizumab’s competitive pricing? Are there any apprehensions?
  • How do payers react to the delay in launch of generic Copaxone 40mg/ml?
  • According to payers, what can Teva do to retain its market share of branded Copaxone 40mg/ml?
  • According to payers, what can Biogen do to retain market share of Tecfidera?
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


More Publications